Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Danish drugmaker Novo Nordisk has mitigation plans in place to minimize or prevent any disruption to its production due to ...

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...